Advances in immunotherapy for hepatocellular carcinoma
10.7659/j.issn.1005-6947.250478
- VernacularTitle:肝细胞癌的免疫治疗进展
- Author:
Min LI
1
;
Xin LIU
;
Dandan YUAN
;
Jianguo WANG
;
Jiang CHEN
;
Dan Gabriel DUDA
Author Information
1. 安徽医科大学第一附属医院肿瘤内科,安徽 合肥 230022;哈佛大学医学院附属麻省总医院Edwin.L.Steele肿瘤生物学实验室/放射肿瘤科,美国波士顿02114
- Publication Type:Journal Article
- Keywords:
Carcinoma,Hepatocellular;
Immunotherapy;
Immune Checkpoint Inhibitors;
Tumor Mi-croenvironment
- From:
Chinese Journal of General Surgery
2025;34(8):1618-1632
- CountryChina
- Language:Chinese
-
Abstract:
Primary liver cancer(PLC)is a prevalent malignancy with high incidence and mortality rates globally.Hepatocellular carcinoma(HCC),primarily resulting from hepatitis B virus infections in Asia,constitutes most PLC cases.Despite advancements in targeted therapies and localized treatments,the 5-year survival rate remains low,indicating limited efficacy of current approaches.The advent of immunotherapy,particularly immune checkpoint inhibitors(ICIs),has brought new hope for patients with PLC.However,the liver's unique immune microenvironment presents significant challenges to the effectiveness of immunotherapy in HCC.This article reviews recent research developments in liver cancer immunotherapy,focusing on ICIs,combination therapies,emerging treatments,and prospective future directions.
